CQ Pharmaceutical's subsidiary drug receives clinical trial acceptance

CQ Pharmaceutical Holding (SZSE:000950) announced that its subsidiary, Chongqing Pharmaceutical (Group) Co., Ltd., has received notification from the NMPA that its application for a clinical trial for Pragelet Tablets has been accepted. The drug, an antiplatelet medication, is intended for the prevention of thrombosis in patients with acute coronary syndrome, stable angina, and previous myocardial infarction undergoing percutaneous coronary intervention. Chongqing Pharmaceutical invested in the development of Pragelet Tablets using technology and exclusive patent authorization from Daiichi Sankyo Company, Limited. The company initially submitted a marketing application in August 2021, which was later withdrawn in July 2023 to improve the submission data. The application for domestic production of Pragelet Tablets was resubmitted at the end of May 2025, leading to the current acceptance for clinical trials. The company cautions that drug development involves uncertainties and advises investors to exercise caution.